Abstract
Hodgkin lymphoma (HL) is a commonly cured malignancy. Unfortunately, patients who are refractory to or relapse after first-line treatment pose a significant therapeutic challenge. There is evidence that these patients are best treated with salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (HDCT/ASCT). This approach cures 40–60% of patients. Outcome is better in patients with low-risk relapse; relapsed patients with poor prognostic scores or those with refractory disease have a poorer prognosis. More aggressive transplant approaches have given promising results in the latter group and are currently under active investigation. For those patients relapsing after HDCT/ASCT, a range of therapeutic options is being offered including other salvage chemotherapy, reduced-intensity allogeneic transplantation, monoclonal antibodies, and novel agents. Generally, patients with relapsed HL should be enrolled in clinical trials.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Josting A, Wolf J, Diehl V. Hodgkin’s disease. Prognostic factors and treatment strategies. Curr Opin Oncol. 2000;12:403–11.
Fisher R, De VV, Hubbard S, et al. Prolonged disease-free survival in Hodgkin disease with MOPP reinduction after first relapse. Ann Intern Med. 1979;90:761–5.
Longo D, Duffey P, Young R, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210–8.
Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin disease failing after primary MOPP/ABVD. J Clin Oncol. 1997;15:528–34.
Josting A, Rueffer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin’s lymphoma – a report from the German Hodgkin’s Lymphoma Study Group (GHSG). Blood. 2000;96(4):1280–6.
Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin disease: a randomised trial. Lancet. 2002;359(9323):2065–71.
Lohri A, Barnett M, Fairey RN, et al. Outcome of treatment of first relapse of Hodgkin disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood. 1991;77(10):2292–8.
Fermè C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin disease. Ann Oncol. 1995;6(6):543–9.
Reece D, Barnett M, Shepherd J, et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/− P) and autologous transplantation for patients with Hodgkin disease who fail to enter a complete remission after combination chemotherapy. Blood. 1995;86:451–8.
Brice P, Bastion Y, Divine M, et al. Analysis of prognostic factors after the first relapse of Hodgkin disease in 187 patients. Cancer. 1996;78(6):1293–9.
Josting A, Franklin J, May M, et al. A new prognostic score based on treatment outcome of patients with relapsed Hodgkin lymphoma registered in the database of the German Hodgkin Lymphoma Study Group (GHSG). J Clin Oncol. 2002;20(1):221–30.
Cannellos G, Young RC, De Vita VD. Combination chemotherapy for advanced Hodgkin’s disease in relapse following extensive radiotherapy. Clin Pharm Ther. 1972;13:750–8.
Santoro A, Viviani S, Villarreal C, et al. Salvage chemotherapy in Hodgkin disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep. 1986;70:343–51.
Josting A, Katay I, Rueffer U, et al. Favorable outcome of patients with relapsed or refractory Hodgkin disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol. 1998;9:289–96.
Biermann PJ, Bagin RG, Jagannath S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long term follow-up in 128 patients. Ann Oncol. 1993;4:767–73.
Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/− cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. Blood. 1994;83(5):1193–9.
Armitage JO, Biermann PJ, Vose JM, et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin’s disease. Am J Med. 1991;91:605–10.
Linch D, Winfield D, Goldstone A, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–4.
Gianni AM, Siena S, Bregni M, Lombardi F, et al. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin’s disease – a 6-year update. Ann Oncol. 1993;4:889–91.
Gianni AM, Bregni M, Siena S. 5-year update of the Milan Cancer Institute randomized trial of high-dose sequential (HDS) vs MACOP-B therapy for diffuse large-cell lymphomas. Proc ASCO. 1994;13:373 (A1263).
Patrone F, Ballestrero A, Ferrando F, Brema F, Moraglio L, Valbonesi M, et al. Four-step high-dose sequential chemotherapy with double hematopoetic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol. 1995;13:840–6.
Shea T, Mason JR, Storniolo AM, et al. Sequential cycles of high-dose carboplatin administered with recombinat human granulocyte-makrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol. 1992;10:464–73.
Gianni AM, Taella C, Bregni M, et al. High-dose sequential chemo-radiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol. 1994;12:503–9.
Caracciolo D, Gavarotti P, Aglietta M, et al. High-dose sequential chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1993;12:621–5.
Norton L, Simon R. The Norton-Simon hypothesis revisited. Canc Treat Rep. 1986;70:163–9.
Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma – results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2003;102(11 Suppl 1):1461.
Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol. 1993;11:2342–50.
Phillips GL, Reece DE, Barnett MJ, et al. Allogeneic marrow transplantation for refractory Hodgkin’s disease. J Clin Oncol. 1989;7:1039–45.
Jones RJ, Piantadosi S, Mann RB, et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol. 1990;8:527–37.
Milpied N, Fielding AK, Pearce RM, et al. Allogeneic bone marrow transplantation is not better than autologous transplant for patients with relapsed Hodgkin’s disease. J Clin Oncol. 1996;14:1291–6.
Carella AM, Cavaliere M, Beltrami G, et al. Immunosuppressive nonmyeloablative allografting as salvage therapy in advanced Hodgkin disease. Haematologica. 2001;86(11):1121–3.
Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3):455–62.
Schmitz N, Sureda A, Robinson S. Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin disease: indications and results. Semin Oncol. 2004;31(1):27–32.
Devizzi L, Santaro A, Bonfante V, et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin’s disease. Ann Oncol. 1994;5:817–20.
Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin disease: results of a multicenter phase II study. J Clin Oncol. 2000;18:2615–9.
Engert A, Diehl V, Schnell R, et al. A phase I study of an anti-CD25 ricin A chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin’s lymphoma. Blood. 1997;15:403–10.
Schnell R, Stark O, Borchmann P, et al. A phase I study with an anti-CD30 ricin A-chain Immunotoxin (Ki-4.dgA) in patients with refractory CD30 positive Hodgkins and non-Hodgkin’s lymphoma. Clin Canc Res. 2002;8(6):1779–86.
Hartmann F, Renner C, Jung W, et al. Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Blood. 1997;15:2042–7.
Borchmann P, Schnell R, Fuss I, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 2002;100:3101–7.
Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003;98(2):310–4.
Borchmann P, Morschhauser F, Parry A, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood. 2003;102(10):3737–3742.
Reiners KS, Gossmann A, von Strandmann EP, et al. Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma. J Immunother. 2009;32(5):508–12.
Evens A, et al. Phase I analysis of the safety and pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor PCI-24781 in relapsed and refractory lymphoma. Blood. 2009;114(22):2726A.
Younes A, et al Personal communication (August 2010).
Younes A, et al. Novel targeted therapy for relapsed Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009;1:507–19.
Crocchiolo R, Canevari C, Assanelli A, et al. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma. 2008;49(4):727–33.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Josting, A., Biermann, P.J. (2011). Relapsed and Refractory Hodgkin Lymphoma. In: Engert, A., Horning, S. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12780-9_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-12780-9_13
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-12779-3
Online ISBN: 978-3-642-12780-9
eBook Packages: MedicineMedicine (R0)